Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

35.05
+1.454.32%
Pre-market: 34.49-0.5600-1.60%04:24 EDT
Volume:3.80M
Turnover:131.24M
Market Cap:2.51B
PE:-5.94
High:35.29
Open:33.91
Low:33.75
Close:33.60
52wk High:56.05
52wk Low:22.72
Shares:71.71M
Float Shares:52.39M
Volume Ratio:2.91
T/O Rate:7.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8984
EPS(LYR):-4.6644
ROE:-91.75%
ROA:-46.76%
PB:6.16
PE(LYR):-7.51

Loading ...

Nov 07, 2024

Major Issues Report

Form 8-K - Current report
Nov 04, 2024

Beneficial Ownership Change

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Oct 31, 2024

Major Issues Report

Form 8-K - Current report
Oct 28, 2024

Major Issues Report

Form 8-K - Current report
Oct 28, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 23, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 09, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 02, 2024

Major Issues Report

Form 8-K - Current report
Sep 25, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 18, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 18, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 11, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 28, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 15, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 08, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 08, 2024

Major Issues Report

Form 8-K - Current report
Jul 03, 2024

Major Issues Report

Form 8-K - Current report
Jun 12, 2024

Major Issues Report

Form 8-K - Current report
May 17, 2024

Major Issues Report

Form 8-K - Current report
May 10, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]